In adenocarcinomas without oncogenic mutations, high IL-1β was linked to improved OS (15.4 months in Q1 vs. 19.0 months in Q4; HR 1.15, 95% CI: 1.05–1.26, p = 0.003) (Supplemental Figure S1B). This evidence concerns the gene IL1B and adenocarcinoma.